This site is intended for healthcare professionals

Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukemia .- Jazz Pharmaceuticals

Read time: 1 mins
Last updated:29th Jul 2021
Published:8th Jul 2021
Jazz Pharmaceuticals plc has announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for injection) for the treatment of adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Condition: Acute Myelogeous Leukemia (AML)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest